Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Surgical Tool Shines Light On Orthopedic Procedures

Executive Summary

Invuity has launched a new illuminated orthopedic surgical tool, adding to its growing line of devices that promise to provide surgeons with improved visibility in an era of smaller and smaller surgical incisions.

You may also be interested in...



Invuity Sees A Clear Path In Minimally Invasive Surgery

Invuity Inc. is bringing a bright new look to the surgical field with a new type of illumination that is giving surgeons the opportunity to see inside the human body better than ever before. The company’s Eigr waveguide system directs standard light through a maze of advanced optical polymer structures that reflect and direct the light so it shines uniformly across – as one surgeon describes it – a “deep, dark incision.” Surgeons say the additional light enables them to do surgeries more quickly and effectively, and Invuity says someday its light might be capable of doing much, much more.

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035628

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel